Literature DB >> 20013621

Early recurrence after surgical resection in patients with pathological stage I non-small cell lung cancer.

R Kawachi1, H Tsukada, Y Nakazato, H Takei, G Furuyashiki, Y Koshi-ishi, T Goya.   

Abstract

INTRODUCTION: Early recurrence is observed even in patients who undergo complete resection and had pathological (p-) stage I. Therefore, we focused on early recurrence, and attempted to elucidate the relationship between early recurrence and clinicopathological factors.
METHODS: Between May 1993 and December 2005, 1201 patients with non-small cell lung cancer (NSCLC) underwent surgical treatment at our institution. Of these, 402 patients who underwent complete resection and had p-stage I NSCLC were retrospectively analyzed for clinicopathological factors. Patients were divided into four groups according to the period between surgery and recurrence (R): no recurrence (NR, n = 331), late recurrence (LR, n = 28, R > 2 years), intermediate recurrence (IR, n = 22, 1 year < R < or = 2 years), and early recurrence (ER, n = 21, R < or = 1 year).
RESULTS: The overall 5-year survival rate for patients with p-stage I was 79.9 %. The overall 5-year survival rates were 91.0 %, 55.6 %, 17.1 %, and 7.5 % for the NR, LR, IR, and ER group, respectively. Preoperative high CEA level, lymphatic permeation, and pleural invasion were proven to be independent factors for overall recurrence. Moreover, multivariate analysis showed that preoperative CEA level, pathological T factor, lymphatic permeation, vascular invasion, and pleural invasion influenced early recurrence within one year.
CONCLUSIONS: The present study demonstrated that preoperative CEA level, pathological T-factor, lymphatic permeation, vascular invasion, and pleural invasion were independent prognostic factors for early recurrence within one year, even in patients with pathological stage I. In patients with these factors, adjuvant therapy may be indicated since this may improve their survival. Copyright Georg Thieme Verlag KG Stuttgart . New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20013621     DOI: 10.1055/s-0029-1185734

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  15 in total

1.  Impact of lymph node occult metastases in stage I non-small cell lung cancer (NSCLC): what is the evidence?

Authors:  Giuseppe Marulli; Marco Mammana; Federico Rea
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

2.  Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer.

Authors:  Mark Shapiro; Gal Akiri; Cynthia Chin; Juan P Wisnivesky; Mary B Beasley; Todd S Weiser; Scott J Swanson; Stuart A Aaronson
Journal:  Ann Surg       Date:  2013-03       Impact factor: 12.969

Review 3.  Recurrence after surgery in patients with NSCLC.

Authors:  Hidetaka Uramoto; Fumihiro Tanaka
Journal:  Transl Lung Cancer Res       Date:  2014-08

4.  Granulocyte-colony-stimulating factor-producing gastric metastasis from large cell type lung cancer.

Authors:  Yasuo Yoshinaga; Hirokazu Kiyozaki; Shinichiro Okada; Fumio Konishi; Shigeki Yamada
Journal:  Clin J Gastroenterol       Date:  2010-12-15

5.  The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis.

Authors:  Wen-Liang Chen; Kuang-Tai Kuo; Teh-Ying Chou; Chien-Lung Chen; Chih-Hao Wang; Yau-Huei Wei; Liang-Shun Wang
Journal:  BMC Cancer       Date:  2012-06-29       Impact factor: 4.430

Review 6.  Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Jun Wang; Jianpeng Chen; Xi Chen; Baocheng Wang; Kainan Li; Jingwang Bi
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

7.  Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients.

Authors:  Tangfeng Lv; Jiawei Zou; Hongbing Liu; Qin Shen; Zhenfeng Lu; XiaoJun Zhou; Xiaonan Wang; Yong Song
Journal:  Oncotarget       Date:  2017-06-20

8.  Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer.

Authors:  William C S Cho; Kien Thiam Tan; Victor W S Ma; Jacky Y C Li; Roger K C Ngan; Wah Cheuk; Timothy T C Yip; Yi-Ting Yang; Shu-Jen Chen
Journal:  Oncotarget       Date:  2018-11-20

9.  Prediction of Postoperative Clinical Outcomes in Resected Stage I Non-Small Cell Lung Cancer Focusing on the Preoperative Glasgow Prognostic Score.

Authors:  Joerg Lindenmann; Nicole Fink-Neuboeck; Valentin Taucher; Martin Pichler; Florian Posch; Luka Brcic; Elisabeth Smolle; Stephan Koter; Josef Smolle; Freyja Maria Smolle-Juettner
Journal:  Cancers (Basel)       Date:  2020-01-08       Impact factor: 6.639

10.  Clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis.

Authors:  Jun Wang; Baocheng Wang; Weipeng Zhao; Yan Guo; Hong Chen; Huili Chu; Xiuju Liang; Jingwang Bi
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.